Effects of botulinum toxin type A in the prevention and treatment of facial hypertrophic scars: A meta‐analysis

Abstract

A meta‐analysis was conducted to comprehensively evaluate the prophylactic and therapeutic efficacy of botulinum toxin type A (BTX‐A) in the treatment of facial hypertrophic scars. Computerised searches were performed in databases, from their inception to November 2023, including Embase, Google Scholar, Cochrane Library, Wanfang, PubMed and China National Knowledge Infrastructure databases, focusing on randomised controlled trials (RCTs) that investigated the use of BTX‐A for treating facial hypertrophic scars. Two researchers independently screened the literature, extracted data and conducted quality assessments. Stata 17.0 software was employed for data analysis. Seventeen RCTs were ultimately included, involving 1605 patients who underwent facial cosmetic surgery. The analysis revealed that compared with conventional treatments, BTX‐A significantly reduced visual analogue scale (VAS) scores (standardized mean difference [SMD]: −3.50, 95% confidence interval [CI]: −5.16 to −1.84, p < 0.001) and Vancouver scar scale (VSS) scores (SMD: −2.86, 95% CI: −4.03 to −1.68, p < 0.001), and narrowed scar width (SMD: −1.80, 95% CI: −2.48 to −1.13, p < 0.001), while also enhancing the overall effectiveness of the treatment. This study indicates that BTX‐A is an effective modality in the prophylaxis and treatment of facial hypertrophic scars, significantly alleviating scar‐related pain and preventing scar widening, and is thus worthy of broader clinical application.